NextCure, Inc. (NXTC)
| Market Cap | 35.14M +161.0% |
| Revenue (ttm) | n/a |
| Net Income | -54.66M |
| EPS | -15.32 |
| Shares Out | 3.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,736 |
| Open | 9.90 |
| Previous Close | 10.25 |
| Day's Range | 9.51 - 10.36 |
| 52-Week Range | 4.60 - 15.74 |
| Beta | 1.43 |
| Analysts | Strong Buy |
| Price Target | 19.33 (+98.46%) |
| Earnings Date | May 7, 2026 |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as w... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NXTC stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 98.46% from the latest price.
News
NextCure initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NextCure (NXTC) with a Buy rating and $25 price target NextCure is a clinical stage biotechnology company focused on developing antibodydrug conjugates for cancer p...
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
“Our SIM0505 program reached critical milestones this quarter, headlined by the U.S. Food and Drug Administration (FDA) granting Fast Track designation for platinum-resistant ovarian cancer and the up...
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, tod...
NextCure initiates dose optimization portion of SIM0505 study
NextCure (NXTC) announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibo...
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
NextCure granted Fast Track Designation for SIM0505 by FDA
NextCure (NXTC) announced that the FDA has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate comp...
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure trading halted, volatility trading pause
09:43 EST NextCure (NXTC) trading halted, volatility trading pause
NextCure expects SIM0505 Phase 1 dose escalation data update in Q2
NextCure (NXTC) provided updates for its two antibody drug conjugate programs and reported a preliminary year-end 2025 cash position. SIM0505: Phase 1 dose escalation data expected in Q2 2026: SIM0505...
NextCure Provides Business Update
BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided upd...
NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference
Lead ADC programs SIM0505 and LNCB74 are progressing in phase I, with data expected in the first half of next year. The company is well-funded into 2027, plans further financing for phase II, and is spinning out non-oncology assets to maintain ADC focus.
NextCure files to sell 2.52M shares of common stock for holders
16:02 EST NextCure (NXTC) files to sell 2.52M shares of common stock for holders
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c...
NextCure announces closing of $21.5M PIPE financing
NextCure (NXTC)announced the closing of its previously announced private placement in public equity. The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP, and...
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced th...
NextCure prices 2.5M shares at $8.52 in private placement
NextCure (NXTC) entered into definitive agreements with the participation of certain institutional and accredited investors, including Ikarian Capital, Squadron Capital Management, Affinity Healthcare...
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced th...
NextCure upgraded to Buy from Neutral at Ladenburg
Ladenburg upgraded NextCure (NXTC) to Buy from Neutral with an $18 price target The firm says SIM0505 has a “clear roadmap” to become a “best-in-class” antibody drug conjugate that targets…
NextCure reports Q3 EPS ($3.22), consensus ($3.98)
“We have made significant progress advancing our promising ADC programs,” said Michael Richman, NextCure’s (NXTC) president and CEO. “We recently began U.S. enrollment in the Phase 1 trial for SIM0505...
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure, Simcere Zaiming announce expansion of Phase 1 trial of SIM0505
NextCure (NXTC) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced that the first patient in the U.S. has been dosed with SIM0505 in the ongoing Phase 1 trial,…